Literature DB >> 35895413

Case Report: Leishmaniasis in a 33-Year-Old Man with Multiple Sclerosis.

Alvaro Guerra-Amor1, Ane Lopez-Gonzalez2, Pau Bosch-Nicolau3, Breogan Rodriguez-Acevedo4, Ana Zabalza4, Elena Sulleiro5, Juan Espinosa-Pereiro3, Maria Luisa Aznar3, Fernando Salvador3, Adrián Sánchez-Montalvá3, Israel Molina3.   

Abstract

Leishmaniasis is a protozoan disease caused by species of genus Leishmania. Immunosuppression increases the risk of severe clinical forms and impairs response to treatment. The expansion of the use of immunomodulatory drugs for different conditions has raised the number of these cases. In this report, we present a case of visceral leishmaniasis in a patient with multiple sclerosis (MS) under fingolimod treatment. He presented with the triad of fever, visceromegaly, and pancytopenia and was diagnosed by the presence of amastigotes in a bone marrow sample. Furthermore, we discuss the previous published cases of MS patients under different immunosuppressant therapies to highlight its risk in endemic areas and suggest a therapeutic approach.

Entities:  

Year:  2022        PMID: 35895413      PMCID: PMC9393455          DOI: 10.4269/ajtmh.22-0117

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   3.707


  20 in total

1.  Protection against progressive leishmaniasis by IFN-beta.

Authors:  Jochen Mattner; Alexandra Wandersee-Steinhäuser; Andreas Pahl; Martin Röllinghoff; Gerard R Majeau; Paula S Hochman; Christian Bogdan
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

2.  Aggressive cutaneous leishmaniasis in a patient with multiple sclerosis treated with fingolimod.

Authors:  R Hernández Clares; P Sánchez Pedreño; E García Vazquez; E Carreón Guarnizo; J E Meca Lallana
Journal:  Neurologia (Engl Ed)       Date:  2017-05-20

Review 3.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 4.  Visceral and Cutaneous Leishmaniasis Recommendations for Solid Organ Transplant Recipients and Donors.

Authors:  Wanessa Trindade Clemente; Paulo Henrique Orlandi Mourão; Francisco Lopez-Medrano; Brian S Schwartz; Carmen García-Donoso; Julian Torre-Cisneros
Journal:  Transplantation       Date:  2018-02       Impact factor: 4.939

Review 5.  Visceral leishmaniasis in immunocompromised: diagnostic and therapeutic approach and evaluation of the recently released IDSA guidelines.

Authors:  Pasquale Pagliano; Tiziana Ascione; Giusy Di Flumeri; Giovanni Boccia; Francesco De Caro
Journal:  Infez Med       Date:  2016-12-01

6.  Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment.

Authors:  A Casabianca; M Marchetti; F Zallio; E Feyles; E Concialdi; E Ferroglio; A Biglino
Journal:  Infection       Date:  2011-05-03       Impact factor: 3.553

Review 7.  Leishmaniasis.

Authors:  Sakib Burza; Simon L Croft; Marleen Boelaert
Journal:  Lancet       Date:  2018-08-17       Impact factor: 79.321

Review 8.  Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy.

Authors:  Aran Groves; Yasuyuki Kihara; Jerold Chun
Journal:  J Neurol Sci       Date:  2013-03-19       Impact factor: 3.181

Review 9.  Treatment of multiple sclerosis - success from bench to bedside.

Authors:  Mar Tintore; Angela Vidal-Jordana; Jaume Sastre-Garriga
Journal:  Nat Rev Neurol       Date:  2019-01       Impact factor: 42.937

10.  Leishmania infantum leishmaniasis in corticosteroid--treated patients.

Authors:  Silvia Pittalis; Emanuele Nicastri; Francesco Spinazzola; Piero Ghirga; Michele De Marco; Maria Grazia Paglia; Pasquale Narciso
Journal:  BMC Infect Dis       Date:  2006-12-18       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.